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The HIV-1 accessory protein Tat has been found to exert profound effects on vascular cell behavior. Recently, Tat has been
found to activate the c-Jun amino-terminal kinase (JNK1, SAPK) MAP kinase in lymphoid cells. We found that purified Tat
rapidly activated JNK1 in human umbilical vein endothelial cells and ECV-304 cells, and coculture of ECV-304 cells with
Tat-transfected HeLa cells resulted in persistent activation of JNK1. In addition, lower doses of Tat potentiated TNFa-induced
JNK1 activation, although higher doses paradoxically diminished JNK1 activation by TNFa. Treatment of ECV-304 cells with
Tat acutely increased intracellular oxidant levels, and Tat-induced oxidant activity was decreased by two structurally distinct
NADPH oxidase inhibitors, diphenylene iodonium and apocynin. Both oxidase inhibitors and the thiol antioxidant N-acetyl
cysteine decreased Tat-induced JNK1 activation in parallel with reduction in oxidant levels. Activation of JNK1 by Tat was also
inhibited by cytochalasin B, suggesting that Tat signaling was dependent upon intact cytoskeletal function. Indeed, JNK1
activation by Tat was associated with actin microfilament rearrangement. We conclude that HIV Tat may cause acute and
persistent activation of the JNK MAP kinase through activation of a specific oxidase. © 2001 Academic PressKey Words: MAP kinase; JNK; SAPK; NADPH oxidase; angiogenesis; vascular endothelium; superoxide; oxidants;
cytoskeleton.
(INTRODUCTION
HIV-infected patients display widespread endothelial
disturbances characterized by abnormal cellular growth,
activation, and differentiation. Aortic endothelia of HIV-
infected patients appear markedly chaotic, with frequent
pyknotic nuclei, bare patches, syncytium formation, and
increased surface expression of the adhesion proteins
VCAM-1 and E-selectin (Zietz et al., 1996). In a recent
study, 15 sequential autopsies of young HIV-infected in-
dividuals dying from diverse causes all demonstrated
intense intimal cell proliferation of the proximal coronary
arteries (Tabib et al., 2000). Further derangements of
vascular cell differentiation and growth may eventually
result in Kaposi’s sarcoma in some patients (Ensoli et al.,
1989), and virtually all HIV-infected individuals harbor
retinal microangiopathy with microaneurysm formation
and loss of capillary cells (Glasgow, 1997; Newsome et
al., 1984).
With a few notable exceptions, however, HIV-1 does
not directly infect the vascular endothelium. It is relevant,
therefore, that HIV-infected cells secrete the accessory
protein Tat, which circulates in the blood of AIDS patients
(Westendorp et al., 1995a). Tat, which possesses pleio-
tropic cytokine and growth factor activities, promotes
endothelial cell migration and matrix invasion in vitro
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62Albini et al., 1995) and induces angiogenesis in vivo
(Albini et al., 1996a). The latter effect has been shown to
be mediated by mimicry of vascular endothelial growth
factor (VEGF) by the midregion basic domain of Tat
(Albini et al., 1996b). Recently, Tat was found to activate
JNK in lymphoid cells (Kumar et al., 1998; Li et al., 1997;
Mischiati et al., 1999). The potential relevance of this
finding to vascular cells lies in the association between
JNK activation and many of the histologic and functional
abnormalities seen in the endothelium of HIV-infected
patients or Tat-treated cultured cells. For instance, JNK
appears to mediate VEGF-induced angiogenesis (Bais et
al., 1998) and cytokine-induced expression of the inflam-
matory adhesion protein E-selectin (Read et al., 1997). In
addition, JNK also appears to mediate both vascular cell
proliferation (Oktay et al., 1999) and cytokine or serum
withdrawal-induced apoptosis of endothelial cells (Yue
et al., 1999).
The mechanism of JNK activation by Tat is not clear.
Interestingly, however, the production of oxidants has
been linked to both JNK activation and Tat exposure.
Chronic exposure to Tat through stable Tat transfection
causes reduction in Mn-SOD expression and increases
biochemical footprints of oxidative stress (Flores et al.,
1993). The acute effects of Tat on oxidant production are
not known. Oxidants themselves appear to be physio-
logic mediators of JNK activation, since oxidant scaven-
gers decrease cytokine-induced JNK activation, and ex-
ogenous oxidants activate JNK (Lo et al., 1996).We therefore hypothesized that Tat may activate JNK
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63TAT AND OXIDASE ACTIVATIONthrough the specific activation of a vascular oxidase. We
found that Tat increases oxidant production acutely in
association with JNK activation and that Tat-induced JNK
activation was suppressed by inhibitors of NADPH oxi-
dase, suggesting that such an oxidase may transduce
Tat signaling.
RESULTS
Tat activates JNK1 in endothelial cells
Tat increased activation of JNK in both human umbili-
cal vein endothelial cells (HUVEC) and ECV-304 cells,
whereas treatment of cells with a sham GST preparation
had no effect (Fig. 1). Exposure of ECV-304 cells to
exogenous Tat activated JNK1 rapidly, with maximal ac-
tivation occurring within 10 min and persisting for at least
2 h (Fig. 2a). Exposure of ECV-304 cells to Tat-producing
HeLa cells for 24 h also resulted in persistent but lower
level activation of JNK1 (Fig. 2b). Activation of JNK1 was
dose-dependent between Tat concentrations of 50 to 500
ng/ml (Fig. 3a).
FIG. 1. ECV-304 cells or HUVEC were exposed to either GST-Tat or
ST activated Tat in both cell types. Histograms represent the ave
xperiments.We further hypothesized that Tat would potentiate the
activity of TNFa, a known JNK agonist, since HIV-1 and
b
iHIV-1 products increase production of TNFa in vitro and
HIV-infected individuals have elevated levels of TNFa in
ivo. In addition, increased levels of TNFa correlate with
ncreased cardiovascular morbidity (Barbaro et al., 2000).
nterestingly, at lower levels (50 ng/ml) Tat augmented
NFa-induced JNK activation (Figs. 3a and 3b), whereas
t 500 ng/ml, Tat diminished TNFa-induced JNK activa-
ion. At the intermediate dose, 200 ng/ml, Tat did not
ffect TNFa-induced JNK activation. Prolonged exposure
of ECV-304 cells to Tat, through coculture with Tat-pro-
ducing HeLa cells, also greatly potentiated JNK activa-
tion by TNFa (Fig. 3c).
at activates JNK1 through an oxidant-dependent
echanism
Exposure of ECV-304 cells to exogenous Tat caused
n abrupt increase in intracellular oxidant production, as
easured by intracellular 29,79-dichlorofluorescin diac-
tate (DCF) fluorescence, within 15–20 min (Fig. 4a).
nterestingly, oxidant activity was diminished not only by
he broad antioxidant N-acetyl cysteine (NAC), but also
ivalent volume of a sham GST preparation for 15 min. GST-Tat but not
elative levels of GST-c-Jun phosphorylation (JNK1 activity) of threean equy two dissimilar NADPH oxidase inhibitors, diphenylene
odonium (DPI) and apocynin. DPI is a flavoprotein inhib-
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64 GU ET AL.itor, commonly used to inhibit the phagocyte NADPH
oxidase (Irani et al., 1997), whereas apocynin appears to
block assembly of the multisubunit NADPH oxidase
(Stolk et al., 1994). NAC and both NADPH oxidase inhib-
itors caused qualitatively similar reductions in Tat-in-
duced JNK1 activation (Fig. 4b), suggesting that an oxi-
dase similar to the phagocyte oxidase may operate in
ECV-304 cells to transduce Tat signals. Inhibitors of xan-
thine oxidase (allopurinol), nitric oxide synthase (nitro-L-
rginine), and mitochondrial respiration (rotenone) had
o effect on Tat-induced JNK1 activation (data not
hown).
at signaling and the cytoskeleton
FIG. 2. Activation of JNK by Tat in ECV-304 cells. (a) Cells were expo
IP kinase method, peaked within 10 min, with a secondary peak at 60 mi
or matched parentals (HeLa-wt) for 24 h. JNK1 activity of HeLa-tat-expos
represent the average relative levels of GST-c-Jun phosphorylation ofActivation of JNK1 by Tat was suppressed by pretreat-
ent of ECV-304 cells with the microfilament destabilizer
a
Tytochalasin B (Fig. 5), suggesting that an intact cy-
oskeleton was required for Tat-initiated signaling. Within
5–30 min of stimulation with Tat, ECV-304 cells devel-
ped peripheral actin bundles and edge ruffles (Fig. 6).
DISCUSSION
Tat exerts protean effects on both immune and vascu-
ar cells, although the signaling pathways through which
t mediates these effects are largely unknown. We found
hat Tat activated JNK in both HUVEC and the HUVEC-
elated cell line ECV-304. Similar to activation of JNK by
at in U937 lymphoblastoid cells (Kumar et al., 1998), but
nlike the situation with Jurkat lymphoblastoid cells (Mis-
hiati et al., 1999), there appeared to be a biphasic
Tat (500 ng/ml) for the indicated times. JNK1 activity, measured by an
CV-304 cells were cocultured with Tat-expressing HeLa cells (HeLa-tat)
-304 cells was greater than that of HeLa-wt-exposed cells. Histograms
three experiments.sed to
n. (b) Ectivation at 10 and 60 min. In contrast to stimulation with
NFa, which produces a transient activation of JNK in
w
t or He
Fa-ind
65TAT AND OXIDASE ACTIVATIONHUVEC which subsides by 60 min (Read et al., 1997), Tat
FIG. 3. Tat potentiated TNFa-induced JNK1 activation. (a) Tat at 50, 2
ith Tat (indicated dose for 105 min) increased (50 ng/ml), had no sign
(100 ng/ml for 15 min). (c) ECV-304 cells were cocultured with HeLa-ta
min) or saline. Coculture with HeLa-tat cells potentiated subsequent TN
of GST-c-Jun phosphorylation of two to five experiments.induced a sustained activation of JNK present for at least
2 h. Indeed, prolonged coculture with Tat-secreting HeLacells, an exposure which may more accurately represent
d 500 ng/ml increased JNK1 activity in ECV-304 cells. (b) Pretreatment
effect (200 ng/ml), or decreased (500 ng/ml) JNK1 activation by TNFa
La-wt cells for 24 h and then stimulated with TNFa (100 ng/ml for 15
uced JNK1 activation. Histograms represent the average relative level00, an
ificantthe in vivo state, increased the basal activity of JNK in
ECV-304 cells.
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66 GU ET AL.Because HIV-infected patients often have elevated lev-
els of TNFa, we also investigated the combined effects
f Tat and TNFa. Pretreatment with a low dose of exog-
enous Tat appeared to potentiate TNFa-induced JNK1
activation acutely, an effect which was even more strik-
ing with prolonged exposure to Tat through coculture
with Tat-secreting HeLa cells. The mechanism of poten-
tiation is not clear, although it is interesting to note that
augmentation of TNFa’s effects has also been noted for
FkB activation as well (Westendorp et al., 1995b), sug-
gesting that Tat and TNFa signaling may intersect at a
FIG. 4. Tat increased intracellular oxidant production and JNK activity
retreatment of cells with NADPH oxidase inhibitors diphenylene iodo
indicated doses decreased oxidant production. Values are the means
ecreased by DPI, Apo, and NAC. Histograms represent the averagerelatively proximal level at or just beyond TRAF-2, prior to
the bifurcation of the NFkB and JNK pathways. Consis-tent with this possibility, TNFa signaling is known to alter
hosphorylation of receptor tyrosine kinases such as
lk-1, a Tat-binding receptor (Guo et al., 2000). Interest-
ngly, higher doses of exogenous Tat inhibited TNFa-
induced JNK1 activation. Again, the basis for this sup-
pressive effect is not known, although one might expect
pretreatment with higher levels of Tat to more robustly
activate counterregulatory phosphatase pathways or de-
crease levels of reduced NADPH (Seve et al., 1999),
which may be necessary for oxidant-dependent TNFa
signaling.
t (500 ng/ml for 10 min) increased DCF fluorescence in ECV-304 cells.
DPI) and apocynin (Apo) or N-acetyl cysteine (NAC) for 20 min at the
of four individual experiments. (b) Tat-induced JNK1 activation was
levels of GST-c-Jun phosphorylation of two to five experiments.. (a) Ta
nium (In addition, we found evidence to suggest that oxi-
dants specifically transduce Tat signaling, resulting in
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67TAT AND OXIDASE ACTIVATIONJNK1 activation. Stable transfection with Tat has been
shown to reduce Mn-SOD expression, thereby increas-
ing chronic oxidative stress (Flores et al., 1993; Westen-
dorp et al., 1995b); our results, however, suggest that
extracellular Tat may rapidly activate a cellular oxidase
which permits JNK signaling to occur. The rapid time
course of oxidant production following Tat exposure
would implicate a receptor-mediated event, although our
studies did not explore this issue. Indeed, however, Tat
immobilized on plastic dishes is capable of activating
JNK in Jurkat T cells (Mischiati et al., 1999), consistent
with this interpretation. Specific and transient production
of oxidants has recently been recognized as a physio-
logic signaling strategy in several MAP kinase-related
signal cassettes, in particular those initiated by TNFa (Lo
et al., 1996). The level at which oxidants affect JNK is
unclear, although they may influence TNFa signaling
roximal to the MAPKKKs ASK1 and MEKK1 but distal to
RAF2 (Gotoh and Cooper, 1998; Natoli et al., 1997). In
ddition, exogenous oxidants appear to activate MAP
inases at or upstream of p21ras GTP loading (Lander et
al., 1995). The participation of endogenous oxidants in
Tat signaling again suggests entry into the JNK activation
pathway at a relatively proximal level by activating a
specific signaling oxidase.
Our data also suggest that the Tat-activated oxidase
has the inhibitor profile of an NAD(P)H oxidase akin to
the phagocyte respiratory burst oxidase. The existence
of such an oxidase has not been proven but is postulated
FIG. 5. Tat-induced JNK1 activation is cytoskeleton-dependent. Pre
decreased JNK1 activation by Tat (500 ng/ml for 15 min). Histogram repr
experiments.in diverse nonphagocytic cells including fibroblasts
(Thannickal and Fanburg, 1995), smooth muscle (Mo-
g
1hazzab and Wolin, 1994), epithelial cells (Cui and Doug-
las, 1997), and endothelial cells (Zulueta et al., 1995).
NADPH oxidase inhibitors inhibit lactosylceramide-in-
duced Erk activation (Bhunia et al., 1997) and activation
of both Erk and JNK in transfectants expressing a con-
stitutively active isoform of p21ras (Irani et al., 1997). Fur-
ther, the rat vascular smooth muscle homolog of the
oxidase subunit p22phox has been cloned, and suppres-
ion of its expression decreases angiotensin II-stimu-
ated oxidant production by smooth muscle cells (Ushio-
ukai et al., 1996).
Finally, our data suggest that Tat signaling may require
functional cytoskeleton. This cytoskeletal requirement
s mirrored in other pathways involved in MAP kinase
ignaling. For instance, active JNK becomes associated
ith the cytoskeleton in part through direct interaction
ith the actin-binding protein ABP-280, and TNFa fails to
ctivate JNK in ABP-280-deficient cells (Marti et al., 1997).
n addition, integrin-dependent anchorage of the cortical
ctin cytoskeleton is required for activation of Erk MAP
inase by many growth factors, including EGF and insu-
in (Tsakiridis et al., 1998), and microfilament disruption
nterrupts growth factor signaling. Further, physical ma-
ipulation of the actin skeleton, for instance by shear
tress, activates both Erk and JNK, in part by phosphor-
lation of the VEGF and Tat receptor Flk1 (Chen et al.,
999). Given the cytoskeletal changes which we observe
ollowing exposure to Tat, it is noteworthy that treatment
f endothelial cells with VEGF also causes marked reor-
nt of ECV-304 cells with cytochalasin B (Cyt. B, 10 mM for 60 min)
the average relative levels of GST-c-Jun phosphorylation of two to fourtreatmeanization of the actin cytoskeleton (Rousseau et al.,
997). Tat itself increases phosphorylation of cytoskel-
w
M
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68 GU ET AL.etal-associated proteins such as p125FAK, paxillin,
p130CAS, and Pyk 2 (Ganju et al., 1998; Milani et al., 1998),
again suggesting intersection of Tat-induced signals
with cytoskeletal-associated events. Finally, the partici-
pation of a phagocyte oxidase-like complex in Tat sig-
naling is intriguing since activation of neutrophils is ac-
companied by assembly of the functional NADPH oxi-
dase on the phagocyte cytoskeleton (el Benna et al.,
1994). Indeed, oxidants appear to mediate taxol-induced
apoptosis (Manna et al., 1998) as well as shape change-
initiated signaling (Kheradmand et al., 1998), both cy-
toskeletal-mediated events.
We conclude that HIV-1 Tat activates JNK1 through the
FIG. 6. Exposure of ECV-304 cells to Tat (500 ng/ml for 30 min) ca
isplaying Tat-induced peripheral f-actin bundling (rhodamine phalloidi
uffle-lamellar structures (arrows) (203).specific generation of oxidants and may intersect TNFa
signal pathways at a relatively proximal level. These
t
sfindings may help explain the abnormal inflammatory
and growth-dysregulated endothelial phenotype charac-
teristic of HIV-infected patients.
MATERIALS AND METHODS
Source of reagents
TNFa (recombinant human) was obtained from Pepro-
Tech. Goat anti-JNK1 (C17) and GST-c-Jun (amino acids
1–79) were from Santa Cruz Biotechnology. [g-32P]ATP
as from NEN; rhodamine phalloidin and DCF were from
olecular Probes. Apocynin (acetovanillone) was ob-
lterations in f-actin staining patterns. Top shows representative cells
original magnification 603). Bottom shows DIC images of Tat-inducedused aained from Aldrich Chemical; NAC, DPI, and cytochala-
in B were from Sigma Chemical.
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69TAT AND OXIDASE ACTIVATIONCell culture
HUVEC were obtained from Clonetics and used at
about passage 4. ECV-304 cells, originating from spon-
taneously immortalized HUVEC (Takahashi et al., 1991),
were grown in DMEM with 10% FBS and routinely used
within 1 day of confluence. For coculture experiments,
HeLa cells stably transfected with HIV-1 Tat (HeLa-tat) or
he parental cell line (HeLa-wt) was utilized (Flores et al.,
993). The production of biologically active Tat was ver-
fied by transfection of HeLa-tat cells with luciferase
under the control of the HIV-1 LTR. HeLa-tat or HeLa-wt
ere grown on six-well Transwell filters (CoStar), then
ransferred to six-well plates containing confluent cul-
ures of ECV-304 cells, and cocultured for 24 h. Medium
as changed to Opti-MEM (Gibco) with 3.75% FBS dur-
ng the coculture experiments.
at purification
SURE Escherichia coli (Stratagene) harboring pGEX-
TK-Tat (86 amino acids) were induced with IPTG and
rown 2 h at 37°C. Tat was purified as previously de-
cribed (Seve et al., 1999). Briefly, cells were harvested
nd sonicated in 50 mM Tris, pH 8.0, 120 mM NaCl, 0.1%
gepal CA-630, 2 mg/ml aprotinin, 1 mg/ml leupeptin, 50
mg/ml PMSF, and 5 mM DTT. GST-Tat in the 12,000g
supernatants was captured with GSH Sepharose. After
extensive washing, Tat was released from GST with
thrombin and separated by centrifugation. In some ex-
periments, Tat was eluted without thrombin cleavage
and used as a GST fusion protein. Activation was found
to be equivalent per microgram of Tat. In addition, treat-
ment of ECV-304 cells with thrombin alone had no effect
on JNK activity. The Tat preparations appeared as a
single band on Coomassie-stained SDS–PAGE gel. Bio-
logical activity was verified by measuring induction of
luciferase activity in HeLa cells transfected with an HIV
LTR–luciferase reporter.
JNK activity
Two 75-cm2 flasks were pooled for each assay. In
coculture experiments, six wells (one plate) were pooled
for each assay. Following exposure to Tat and/or TNFa,
cells were washed and lysed in cold RIPA (50 mM Tris,
pH 7.2, 150 mM NaCl, 0.1% SDS, 0.5% Na deoxycholate,
1% Triton X-100, 10 mM Na pyrophosphate, 25 mM Na
glycerophosphate, 2 mM sodium orthovanadate, 10
mg/ml aprotinin, 10 mg/ml leupeptin, and 1 mM PMSF)
and drawn through a 23-gauge needle three times. Fol-
lowing centrifugation at 12,000g for 10 min at 4°C, su-
pernatants were adjusted for protein content, precleared
with protein G-agarose (Pharmacia), immunoprecipitated
with anti-JNK1 (30 min at 4°C) and protein G-agarose (90
min at 4°C), and washed extensively. Immunoblots of the
immunoprecipitate demonstrated a single band of ap-proximately 46 kDa. The immunoprecipitated JNK1 was
assayed for kinase activity in kinase buffer (25 mM
HEPES, pH 7.6, 20 mM b-glycerophosphate, 20 mM
gCl2, 2 mM DTT, 0.1 mM sodium orthovanadate, 20 mM
-nitrophenyl phosphate, 20 mM ATP) by addition of 5
mCi [g-32P]ATP and 2 mg c-Jun. After a 30-min incubation
t 30°C, reactions were stopped by addition of Laemmli
uffer and samples resolved by SDS–PAGE.
CF fluorescence
Oxidant activity was measured by fluorescence of in-
racellular DCF. ECV-304 cells were washed three times
ith Hanks’ buffered salt solution (HBSS) to remove any
erum-associated esterases and then incubated with 80
mM DCF in HBSS for 20 min at 37°C, in the presence or
absence of oxidase inhibitors. Cells were then washed
and exposed to Tat in Opti-MEM with 3.75% FBS. After a
10-min incubation at 37°C, cells were washed in calci-
um/magnesium-free HBSS, dislodged and separated
with trypsin/EDTA (Gibco), and analyzed by flow cytom-
etry (Becton–Dickinson). Mean fluorescence values of
four separate experiments were compared using ANOVA
with Student–Neuman–Keuls comparison test.
Microscopy
Glass chamber slides (Nunc) were coated with fi-
bronectin prior to seeding with ECV-304 cells. Following
exposure to Tat, cells were examined using Nomarski
differential interference contrast optics (Nikon). For
f-actin staining, cells were fixed with 3% paraformalde-
hyde in PBS and then permeabilized in 0.5% Triton X-100,
50 mM NaCl, 3 mM MgCl2, 200 mM sucrose, 10 mM
HEPES, pH 7.4, and 0.2% Na azide. Cells were blocked
with 3% BSA in PBS, washed, and incubated with 1 U
rhodamine phalloidin at 24°C for 30 min. Following two
washes with 1% BSA in PBS and two washes with PBS,
slides were coverslipped using ProLong antifade (Mo-
lecular Probes) and examined with a confocal laser
scanning microscope (Bio-Rad MRC-600).
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